Reni J. Benjamin
Stock Analyst at JMP Securities
(2.14)
# 2,318
Out of 4,980 analysts
8
Total ratings
50%
Success rate
9.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $18.60 | +115.05% | 2 | Sep 3, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $28.40 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $1.43 | +109.79% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $1.22 | +145.90% | 1 | Aug 18, 2025 | |
| BCAB BioAtla | Downgrades: Market Perform | n/a | $0.77 | - | 1 | Aug 13, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $22 → $10 | $7.02 | +42.45% | 1 | Aug 12, 2025 | |
| KURA Kura Oncology | Maintains: Market Outperform | $28 → $24 | $8.83 | +171.95% | 1 | Aug 11, 2025 |
Summit Therapeutics
Sep 3, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.60
Upside: +115.05%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $28.40
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $1.43
Upside: +109.79%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $1.22
Upside: +145.90%
BioAtla
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.77
Upside: -
Bicycle Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $7.02
Upside: +42.45%
Kura Oncology
Aug 11, 2025
Maintains: Market Outperform
Price Target: $28 → $24
Current: $8.83
Upside: +171.95%